What is CAR T-Cell Therapy?
Chimeric Antigen Receptor T-cell therapy, commonly known as CAR T-cell therapy, represents a revolutionary approach in cancer treatment. This personalized immunotherapy involves extracting a patient's own T-cells—the immune system's key fighters—from their blood. These T-cells are then genetically engineered in a laboratory to express a chimeric antigen receptor (CAR). The CAR acts like a GPS, directing the T-cells to specifically target and destroy cancer cells that display certain proteins, such as CD19 on B-cell lymphomas.
The process unfolds in several precise steps: First, leukapheresis collects the T-cells. Next, a viral vector inserts the CAR gene into the T-cells. The modified cells are expanded in bioreactors for 7-14 days to reach billions in number. Quality checks ensure purity and potency before infusion back into the patient, often preceded by lymphodepleting chemotherapy to make space for the CAR T-cells. Once inside, they proliferate and attack the cancer, potentially providing long-term remission with a single treatment.
In New Zealand, where blood cancers affect hundreds annually, this therapy addresses unmet needs for patients with relapsed or refractory diseases who have exhausted standard options like chemotherapy and stem cell transplants.
The Burden of Blood Cancers in New Zealand
Blood cancers, including lymphomas, leukaemias, and myelomas, rank as the fourth most common cancer type in Aotearoa New Zealand. With over 30,000 new cancer diagnoses projected for 2025 rising to 45,000 by 2044, blood cancers contribute significantly, impacting around 1,300 people yearly. Māori and Pacific peoples face higher incidence and poorer outcomes, underscoring inequities that local innovations like CAR T-cell therapy could help mitigate. Large B-cell non-Hodgkin lymphoma (LBCL), the focus of New Zealand's pioneering trial, sees patients often relapsing after initial treatments, leaving them with limited prospects.
Currently, eligible Kiwis must travel overseas for commercial CAR T therapies, costing upwards of NZ$500,000 per patient, excluding travel and accommodation. Stories abound of patients fundraising or seeking cheaper options in China at around NZ$180,000, highlighting the urgent need for domestic solutions.
Genesis of New Zealand's CAR T-Cell Program at Malaghan Institute
The Malaghan Institute of Medical Research in Wellington spearheaded New Zealand's first CAR T-cell initiative through the ENABLE trial, launched in 2019. Led by Clinical Director Professor Rob Weinkove—a haematologist with affiliations to the University of Auckland and PhD from Otago—the program developed a third-generation CD19-targeted CAR T-cell product (WZTL-002) in partnership with Wellington Zhaotai Therapies.
This homegrown therapy incorporates dual co-stimulatory domains (CD28 and TLR2) for enhanced persistence and safety, distinguishing it from second-generation commercial products. From scratch, the team built GMP facilities, navigated regulations, and overcame manufacturing hurdles on a modest budget.
Details of the ENABLE Phase 1 Clinical Trial
The ENABLE-1 trial (NCT04049513) was a first-in-human, dose-escalation and expansion study for adults with relapsed/refractory B-cell non-Hodgkin lymphoma post-multiple therapies. Thirty patients were treated at Wellington Hospital, with the first 21 in dose escalation and nine in expansion at the recommended phase 2 dose (RP2D), incorporating outpatient management.
- Patient selection: Those unfit for further standard care.
- Dosing: Escalated to find optimal safe level.
- Manufacturing: Initial manual, then automated via BioOra's Cocoon platform for scalability.
- Follow-up: Ongoing monitoring for response and side effects.
New Zealand Blood Service supported apheresis, ensuring a fully local supply chain.
Impressive Phase 1 Results and Research Publications
Preliminary dose-escalation data presented at ASH 2023 showed a 52% complete response (CR) rate at three months, with no neurotoxicity or severe cytokine release syndrome (CRS)—far better than commercial therapies' 20-30% severe side effect rates. Full phase 1 analysis at ASH 2024 confirmed 52% CR in escalation (n=21) and 56% in expansion (n=9), enabling outpatient delivery and cost savings.
These findings, poised for peer-reviewed publication, benchmark favorably globally, positioning New Zealand as a leader in academic CAR T development. For full details, see the ASH 2024 abstract.
Photo by Yu Chen Lin 育辰 on Unsplash
Innovations in Manufacturing and Safety
BioOra, incubated at Malaghan with Bridgewest Ventures backing, pioneered automated CAR T production using closed-system bioreactors. This reduces labor, contamination risks, and costs—critical for public health systems. The third-generation design minimizes exhaustion and toxicity, allowing home administration post-infusion.
- Benefits: Scalable, consistent, outpatient-friendly.
- Risks mitigated: Low CRS (grade 1-2 only), zero ICANS (neurotoxicity).
- Comparisons: Safer than Yescarta/Kymriah.
Academic Contributions from New Zealand Universities
Higher education plays a pivotal role. Prof. Weinkove's University of Auckland profile underscores cross-institutional collaboration, while Otago's McLellan lab enhances CAR T for solid tumors. Auckland's Centre for Cancer Research, led by Dr. Alicia Didsbury, advances cell/gene therapies affordability. Victoria University Wellington hosts theses on CAR T delivery optimization. These efforts train the next generation of researchers, with opportunities in research jobs and clinical research jobs.
Explore NZ higher ed tools for biotech careers.
Patient Impacts and Stories
Phase 1 participants, out of options, achieved durable remissions. Over half saw no detectable cancer at three months, with some cancer-free years later. Media highlights 'mouse poet' and businessman cases, crediting the therapy for second chances. This humanizes the research, fueling calls for equity.
Challenges and Urgent Calls for Funding
Despite success, Phase 2 (ENABLE-2, NCT06486051) requires $15 million for 60 patients across Wellington, Auckland, and Christchurch. Malaghan fundraises privately amid government funding gaps, as overseas access remains inaccessible. Experts urge public investment in BioOra's facility to serve 50-80 patients yearly, preventing 'brain drain' of talent. View trial on ClinicalTrials.gov.
Phase 2 and Path to Registration
ENABLE-2, underway since July 2024, tests efficacy earlier in treatment (2nd/3rd line), aiming for NZ/Australia approval. Multi-site design builds infrastructure. Success could make CAR T standard care, expanding to other cancers via ongoing lab work.
Photo by Yu Chen Lin 育辰 on Unsplash
Future Outlook for NZ Cancer Research and Higher Education
This breakthrough elevates New Zealand's global standing in immunotherapy, fostering biotech hubs. Universities gear up for trials, creating postdoc and research assistant jobs. Broader impacts include economic growth and health sovereignty. For career advice, visit higher ed career advice.
In conclusion, the Phase 1 success demands action. Explore opportunities at university jobs, higher ed jobs, rate my professor, and career advice.